Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases

JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Civallero, Monica, Cosenza, Maria, Pozzi, Samantha, Sacchi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732767/
https://www.ncbi.nlm.nih.gov/pubmed/29262601
http://dx.doi.org/10.18632/oncotarget.21951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732767/
https://www.ncbi.nlm.nih.gov/pubmed/29262601
http://dx.doi.org/10.18632/oncotarget.21951

Ejemplares similares